GlassScriptPhysician profile
Michael C James
NPI 1215916218
$509.47
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $23.81 · 2021: $212.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $112.11 | 2019 | |
| Coloplast Corp | $103.71 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $33.26 | 2019 | |
| Axonics, INC. | $32.45 | 2021 | |
| Convatec INC. | $27.52 | 2021 | |
| Dendreon Pharmaceuticals LLC | $26.40 | 2019 | |
| Myovant Sciences INC. | $24.37 | 2021 | |
| Abbvie INC. | $23.39 | 2019 | |
| Laborie Medical Technologies Corp. | $22.45 | 2021 | |
| Hollister Incorporated | $20.03 | 2019 | |
| 180 Medical, INC. | $16.70 | 2021 | |
| Allergan, INC. | $15.06 | 2019 | |
| Photocure INC | $15.02 | 2021 | |
| Urogen Pharma, INC. | $13.24 | 2021 | |
| Antares Pharma, INC. | $12.07 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $11.69 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.